Topic: preclinical research
AbbVie and Principia are ending an autoimmunity-focused deal, with Principia regaining the rights to the immunoproteasome inhibitor program.
Charles River has added another string to its early-stage R&D bow by acquiring preclinical services firm Citoxlab for $510 million in cash.
eGenesis is bringing on William “Wes” Westlin, Ph.D., to help head up its xenotransplantation R&D as executive vice president.
Neurodegenerative disease startup QurAlis has extended the seed round it first announced in April, bringing its total funding up to $5.5 million.
Intellia Therapeutics’ clinical development head, Adel Nada, left to serve as the first chief medical officer of Casebia Therapeutics.
Qpex Biopharma launched as a new infectious disease company, simultaneously obtaining $33 million and preclinical assets from The Medicines Company.
Nimbus Therapeutics promoted CFO Jeb Keiper to president and CEO, as it eyes clinical development for cancer, autoimmune and metabolic diseases.
DNAlite Therapeutics gathered $1.5 million in seed money for gene therapies that slip through the mucus typically blocking access to the GI tract.
Merck and HitGen upsized their licensing agreement to a full discovery collaboration, screening DNA-encoded libraries of billions of small molecules.
A startup exited stealth mode to push a new class of drugs that could help regenerate nerve cells’ insulating myelin sheaths in diseases such as MS.